A bibliometric analysis of the research landscape of lenalidomide resistance in multiple myeloma
Ruihua Li, Lingjuan Huang, Zhuanghui Hao, Xue Zhao, Jinqian Dai, Qin Gao, Yani Gao · 2026
Read A bibliometric analysis of the research landscape of lenalidomide resistance in multiple myeloma by Ruihua Li, Lingjuan Huang, Zhuanghui Hao, Xue Zhao, Jinqian Dai, Qin Gao, Yani Gao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13469270.txt.
Description
Ruihua Li and colleagues mapped lenalidomide resistance research in 2026 in multiple myeloma, where resistance to the cornerstone drug eventually strikes nearly all patients. The team searched Web of Science from 2005 to 2025, mapping trends, collaborations, and clusters with three bibliometric tools. The United States led with 961 papers, ahead of China at 235 and Italy at 183.
Harvard topped institutions at 502 papers, while the journal Blood led citations at 16,080, and Philippe Moreau carried the highest H-index. Four clusters centred on combination therapy, cell mechanisms and apoptosis, proteasome inhibitors, and monoclonal antibodies, with recent bursts on consensus and phase 3 trials. Future work should target STAT3/NF-kB pathways and build consensus on next-generation combinations.
Catalog record
| CREATOR | Ruihua Li, Lingjuan Huang, Zhuanghui Hao, Xue Zhao, Jinqian Dai, Qin Gao, Yani Gao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |